New pill for rare bone disease enters human testing
NCT ID NCT07179640
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 24 times
Summary
This study tests a new oral drug called ALE1 for hypophosphatasia (HPP), a rare bone disease. It is the first time this drug is given to humans, so the main goal is to check its safety and how the body processes it. The trial includes healthy adults and adults with HPP, and some participants will receive a placebo (inactive pill) for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA (HPP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit
RECRUITINGLeeds, United Kingdom
Contact Phone: •••-•••-••••
-
New Zealand Clinical Research
RECRUITINGGrafton, Auckland, 1010, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.